AstraZeneca beat analyst expectations for its second-quarter revenue on strong demand for its cancer, rare disease and heart disease medicines.
Tag Archive for: AstraZeneca
AstraZeneca is proposing to use Imfinzi for resectable non-small cell lung cancer in the perioperative setting—both before and after surgical resection of the tumor. However, ahead of Thursday’s advisory committee meeting, FDA staffers have expressed concerns.
WPP announced AstraZeneca has appointed the network, led by VML Health, to the pharma giant’s roster for its U.S. and global oncology creative business. The WPP team will be based out of the United States and UK, and will also be comprised of Grey Health and Ogilvy Health.
AstraZeneca said on Monday that the European Union drug regulator has accepted a market authorization application for its investigational COVID-19 prevention drug, sipavibart, for an accelerated assessment.
China has approved the use of AstraZeneca’s blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company said today.
The blockbuster cancer drug Imfinzi has failed as a follow-up therapy to improve disease-free survival in a late-stage trial in patients with a type of early-stage lung cancer.
AstraZeneca on Tuesday announced that its AKT inhibitor Truqap, when used in combination with paclitaxel, failed to meet its primary efficacy endpoint in the Phase III CAPItello-290 study in patients with metastatic triple-negative breast cancer.
The approval came after a late stage trial showed that Imfinzi along with chemotherapy drugs carboplatin and paclitaxel, then followed by Imfinzi by itself, reduced the risk of disease progression or death by 58% in specific endometrial cancer patients, compared to chemotherapy alone.
Yesterday Amgen secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two rare diseases.
AstraZeneca and Daiichi Sankyo on Monday revealed additional data from the Phase III TROPION-Lung01 study, showing that their investigational antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) failed to significantly improve overall survival in non-small cell lung cancer patients.